Caption Management LLC Cuts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Caption Management LLC lessened its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 59.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,844 shares of the company’s stock after selling 78,556 shares during the quarter. Caption Management LLC’s holdings in Pacira BioSciences were worth $1,014,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in shares of Pacira BioSciences by 0.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company’s stock valued at $37,541,000 after buying an additional 13,604 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Pacira BioSciences by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company’s stock valued at $20,578,000 after acquiring an additional 5,071 shares during the period. Northern Trust Corp boosted its position in shares of Pacira BioSciences by 30.8% during the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company’s stock worth $11,622,000 after purchasing an additional 145,205 shares in the last quarter. Impax Asset Management Group plc grew its stake in shares of Pacira BioSciences by 14.8% during the 4th quarter. Impax Asset Management Group plc now owns 540,027 shares of the company’s stock worth $10,174,000 after purchasing an additional 69,424 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Pacira BioSciences by 16.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock valued at $9,462,000 after purchasing an additional 70,307 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Trading Down 2.6 %

Pacira BioSciences stock opened at $25.15 on Wednesday. The stock has a 50-day moving average price of $24.64 and a 200 day moving average price of $21.97. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The stock has a market cap of $1.16 billion, a PE ratio of -12.39 and a beta of 0.56. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Analysts Set New Price Targets

PCRX has been the topic of several recent analyst reports. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays upped their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their price objective for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 8th. Finally, HC Wainwright lifted their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $26.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.